Setback for UK pharma as government sets unexpectedly high VPAG payback rate in 2025
Once VPAG was introduced in early 2024, the initial headline payback value was only 15.1% for newer medicines in Q2–Q4.
Pricing and Market Access
Denmark’s HTA evolution
Navigating medicine pricing in Turkiye: the pharmaceutical Euro exchange rate
Exploring drug shortages in European markets: the causes, analysis, and response
Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
South Korean pricing reform suggests more flexible drug reimbursement negotiations
Unresolved clawback issues obstruct Greece’s potential pharmaceutical framework agreement
Keytruda and Opdivo: a decade review
